This inventor holds 1 USPTO granted patent. Top assignees: Asieris Pharmaceuticals (Shanghai) Co., Ltd., Jiangsu Yahong Meditech Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: The Innovations of Shuai Shen
Introduction
Shuai Shen is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative patent related to nitroxoline prodrugs. His work exemplifies the intersection of chemistry and medicine, showcasing the potential for improved therapeutic solutions.
Latest Patents
Shuai Shen holds a patent for a pharmaceutical composition containing a nitroxoline prodrug, along with its preparation method and application. The composition includes 100 parts of an active pharmaceutical ingredient, 22.5-320 parts of filler, 0-40 parts of disintegrant, 0-95 parts of binding agent, and 2-30 parts of lubricant. This formulation demonstrates excellent stability, dissolution properties, and pharmacokinetic characteristics, making it a valuable addition to pharmaceutical science.
Career Highlights
Throughout his career, Shuai Shen has worked with prominent companies in the pharmaceutical industry. He has been associated with Jiangsu Yahong Meditech Co., Ltd. and Asieris Pharmaceuticals (Shanghai) Co., Ltd. His experience in these organizations has contributed to his expertise in drug formulation and development.
Collaborations
Shuai Shen has collaborated with notable colleagues in his field, including Jie Chen and Youbin Wu. These partnerships have likely enhanced his research and development efforts, leading to innovative solutions in pharmaceuticals.
Conclusion
Shuai Shen's contributions to pharmaceutical innovation, particularly through his patent on nitroxoline prodrugs, highlight his role as a significant inventor in the industry. His work continues to influence the development of effective pharmaceutical compositions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile